Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Neumora Therapeutics (NASDAQ:NMRA) from a strong sell rating to a sell rating in a report published on Saturday.

Several other equities analysts have also commented on the stock. Mizuho dropped their price target on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, June 18th. Needham & Company LLC decreased their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Royal Bank Of Canada lowered their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $6.57.

Neumora Therapeutics Stock Down 7.5%

NMRA opened at $1.60 on Friday. Neumora Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.65. The business has a 50-day moving average of $1.61 and a two-hundred day moving average of $2.12. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. The stock has a market capitalization of $296.45 million, a price-to-earnings ratio of -1.30 and a beta of 2.75.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, research analysts expect that Neumora Therapeutics will post -0.93 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NMRA. HBK Sorce Advisory LLC purchased a new stake in Neumora Therapeutics during the second quarter worth approximately $26,000. Hsbc Holdings PLC purchased a new stake in Neumora Therapeutics during the 4th quarter worth $27,000. Virtu Financial LLC purchased a new stake in Neumora Therapeutics during the 3rd quarter worth $31,000. Fred Alger Management LLC acquired a new stake in Neumora Therapeutics in the 4th quarter valued at $40,000. Finally, Canada Pension Plan Investment Board purchased a new position in Neumora Therapeutics in the second quarter valued at about $41,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.